How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( NASDAQ: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at Bernstein's 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.
Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in a fireside chat at Bernstein's 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.
How Do Investors Really Feel About Royalty Pharma? - Royalty Pharma ( NASDAQ:RPRX )
Royalty Pharma's RPRX short interest as a percent of float has risen 18.13% since its last report. According to exchange reported data, there are now 16.62 million shares sold short, which is 3.91% of all regular shares that are available for trading.
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation - Royalty Pharma ( NASDAQ:RPRX )
On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma's platform value
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation
NEW YORK, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) will host an Investor Day in New York City today. Senior executives will provide an update on the company's plans to drive shareholder value creation through its unique business model and capabilities in the large ...
Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market
NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive ...
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
NEW YORK, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following ( collectively, the "Notes" ...
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - Royalty Pharma ( NASDAQ:RPRX ) , Zenas BioPharma ( NASDAQ:ZBIO )
Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
NEW YORK and WALTHAM, Mass., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) and Zenas BioPharma, Inc. ( Nasdaq: ZBIO ) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab.
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease ...
What's Going On With BeOne Medicines Stock Monday? - Royalty Pharma ( NASDAQ:RPRX ) , BeOne Medicines ( NASDAQ:ONC ) , Amgen ( NASDAQ:AMGN )
BeOne to sell Imdelltra royalties for $885 million upfront, plus $65 million option within a year. Royalty deal excludes China, with profit-sharing on sales above $1.5 billion annually. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → BeOne Medicines ...
Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it has acquired a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager ( BiTE ) , from BeOne Medicines for $885 million upfront.
Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million - Royalty Pharma ( NASDAQ:RPRX )
Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer ( ES-SCLC ) marketed by Amgen Royalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 ...
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025.
Theravance Sales Jump 83 Percent
Theravance Biopharma ( NASDAQ:TBPH ) , a biopharmaceutical company focused on respiratory medicines and rare disease therapeutics, reported its Q2 2025 results on August 12, 2025. The company's revenue ( GAAP ) grew to $26.2 million, slightly ahead of analyst estimates at $25.93 million.
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today - Royalty Pharma ( NASDAQ:RPRX )
Royalty Pharma RPRX has outperformed the market over the past 15 years by 36.41% on an annualized basis producing an average annual return of 48.86%. Currently, Royalty Pharma has a market capitalization of $15.45 billion.
Royalty Pharma ( RPRX ) Q2 Receipts Up 20%
Royalty Pharma Plc ( NASDAQ:RPRX ) , a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts-its closest revenue proxy-rose 11% to $672 million but landed just under the $672.99 million analyst ...
Royalty Pharma ( RPRX ) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Royalty Pharma ( RPRX ) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.
Royalty Pharma ( RPRX ) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Royalty Pharma Declares Third Quarter 2025 Dividend
NEW YORK, July 18, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.
Royalty Pharma Declares Third Quarter 2025 Dividend - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, July 18, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc RPRX has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of ...
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors
NEW YORK, July 17, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the appointment of Carole Ho and Elizabeth ( Bess ) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a ...
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors - Royalty Pharma ( NASDAQ:RPRX )
Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90% Underscores Royalty Pharma's commitment to enhanced corporate governance following acquisition of its external manager
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
NEW YORK, July 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at ...
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, July 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.
Should You Invest in the iShares U.S. Pharmaceuticals ETF ( IHE ) ?
Sector ETF report for ...
Revolution Medicines To Advance Lead Cancer Drug With Funding Worth $2B - Royalty Pharma ( NASDAQ:RPRX ) , Revolution Medicines ( NASDAQ:RVMD )
The deal includes up to $1.25 billion in royalties and $750M in corporate debt for daraxonrasib. Royalty rate on sales over $8 billion drops to zero under 15-year funding agreement. See how Matt Maley is positioning for global volatility, sector rotations, and macro shifts-live this Wednesday, ...
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
NEW YORK, June 24, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million.
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion - Royalty Pharma ( NASDAQ:RPRX )
Up to $1.25 billion ( $250 million upfront ) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS ( ON ) Inhibitor Portfolio for Patients with RAS-Addicted Cancers - Revolution Medicines ( NASDAQ:RVMD )
Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debt Company moving forward with independent global commercialization strategy to prioritize patient reach and maximize shareholder value
A Look Into Royalty Pharma Inc's Price Over Earnings - Royalty Pharma ( NASDAQ:RPRX )
In the current market session, Royalty Pharma Inc. RPRX stock price is at $34.26, after a 1.72% drop. However, over the past month, the company's stock went up by 7.75%, and in the past year, by 30.95%.
How Is The Market Feeling About Royalty Pharma? - Royalty Pharma ( NASDAQ:RPRX )
Royalty Pharma's RPRX short percent of float has risen 40.0% since its last report. The company recently reported that it has 29.02 million shares sold short, which is 7.0% of all regular shares that are available for trading.
Kailera Therapeutics Appoints Adam Koppel and Christopher Hite to Board of Directors
BOSTON and SAN DIEGO, June 05, 2025 ( GLOBE NEWSWIRE ) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the appointments of Adam Koppel ...
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, June 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
Royalty Pharma Completes the Acquisition of Its External Manager
NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ( "RP Management" ) . The acquisition received overwhelming support from Royalty Pharma's shareholders, with ...
Royalty Pharma Completes the Acquisition of Its External Manager - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ( "RP Management" ) . The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of ...
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
NEW YORK, May 12, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of ...
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition - Royalty Pharma ( NASDAQ:RPRX )
Received overwhelming shareholder approval with 99.9% of votes cast in favor Simplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
